JPH0574377B2 - - Google Patents
Info
- Publication number
- JPH0574377B2 JPH0574377B2 JP61257931A JP25793186A JPH0574377B2 JP H0574377 B2 JPH0574377 B2 JP H0574377B2 JP 61257931 A JP61257931 A JP 61257931A JP 25793186 A JP25793186 A JP 25793186A JP H0574377 B2 JPH0574377 B2 JP H0574377B2
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- blood
- pump
- collection
- line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004369 blood Anatomy 0.000 claims description 56
- 239000008280 blood Substances 0.000 claims description 56
- 238000005070 sampling Methods 0.000 claims description 17
- 238000001816 cooling Methods 0.000 claims description 13
- 210000000601 blood cell Anatomy 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 9
- 210000003462 vein Anatomy 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims 2
- 238000010241 blood sampling Methods 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000012530 fluid Substances 0.000 description 8
- 238000005345 coagulation Methods 0.000 description 7
- 230000015271 coagulation Effects 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 229940127219 anticoagulant drug Drugs 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Description
【発明の詳細な説明】
＜産業上の利用分野＞
本発明は採漿装置に関する。さらに詳しくは本
発明は、採取血漿の中に含まれる第因子凝固活
性の減退を抑制し、また血漿の凍結までの時間を
短縮させることのできを採漿装置に関する。DETAILED DESCRIPTION OF THE INVENTION <Industrial Application Field> The present invention relates to a plasma sampling device. More specifically, the present invention relates to a plasma collection device capable of suppressing decline in factor coagulation activity contained in collected plasma and shortening the time required for freezing the plasma.
＜従来の技術＞
近年、医療技術の進歩に伴ない、従来の全血を
輸血する方法から、血漿などの必要な成分だけを
分離して使用する成分輸血療法が急速に普及して
きており、血液から血漿だけを分離・採取して、
残りの血球濃厚液を供血者に返血する血漿採取方
法が導入されている。<Conventional technology> In recent years, with advances in medical technology, component transfusion therapy, in which only necessary components such as plasma are separated and used, has rapidly become popular, replacing the conventional method of transfusing whole blood. Separate and collect only plasma from
Plasma collection methods have been introduced in which the remaining blood cell concentrate is returned to the donor.
そしてこのような血漿採取方法としては、膜型
あるいは遠心分離型採漿装置を用いて、供血者の
静脈から血液を体外に流出させ、流出した血液か
ら血漿分離器を用いて血漿を分離させ、分離した
血漿を血漿容器に採取し、残りの血球濃厚液を供
血者に返血する方法が知られている。分離・採取
された血漿は第因子を含有するクリオプレシピ
テートに製剤され、またさらに、第因子が分
画・製剤されて血友病の治療に使用されることが
ある。ところが、従来採漿装置により分離・採取
された血漿は、冷蔵庫に入庫するまでの間、体温
に近い温度のまま室温に放置されているのが現状
であり、従つて血漿の中に含まれる第因子の凝
固活性がその間に減退していた。そこで第因子
を必要とする血漿は、分離・採取された後できる
だけ速やかに−40℃以下の低温に凍結して保持す
る必要がある。 Such a plasma collection method involves draining blood from the blood donor's veins outside the body using a membrane-type or centrifugal plasma collection device, and separating plasma from the drained blood using a plasma separator. A known method is to collect separated plasma into a plasma container and return the remaining blood cell concentrate to the donor. The separated and collected plasma is formulated into cryoprecipitate containing factor factor, and factor factor may also be fractionated and formulated for use in the treatment of hemophilia. However, the current situation is that plasma separated and collected using conventional plasma collection devices is left at room temperature at a temperature close to body temperature until it is stored in a refrigerator. The coagulation activity of the factor had decreased during that time. Therefore, plasma, which requires factor factor, needs to be frozen and maintained at a low temperature of -40°C or lower as soon as possible after being separated and collected.
＜発明が解決しようとする問題点＞
しかしながら、現在の採漿装置においては、血
漿を採取・分離してから低温の−40℃以下に凍結
保存するまでの時間が、採漿時間を含めて１時間
以上を要し、とくに血漿採取中には分離・採取さ
れた血漿が室温に放置されており、その間に採取
血漿の中に含まれている第因子凝固活性の減退
が進行するので問題であつた。また分離・採取後
の室温に放置された血漿は直接−40℃以下の冷凍
庫に入庫されるが、凍結されるまでに長時間を要
し、従つて凍結するまでの間に第因子凝固活性
が減退する虞れがあり問題であつた。<Problems to be Solved by the Invention> However, with current plasma sampling devices, the time from collecting and separating plasma to freezing and preserving it at a low temperature of -40°C or lower is approximately 1 hour, including the plasma sampling time. This is a problem because the separated and collected plasma is left at room temperature during plasma collection, and during that time the factor coagulation activity contained in the collected plasma progresses to decline. Ta. In addition, plasma left at room temperature after separation and collection is stored directly in a freezer at -40°C or lower, but it takes a long time to freeze, and the factor coagulation activity is lost during the freezing process. This was a problem because there was a risk that it would decline.
本発明は上記問題点に鑑みてなされたもので、
その目的とするところは採取血漿の中に含まれる
第因子凝固活性の減退を抑制すると共に、血漿
の凍結までの時間を短縮させることのできる採漿
装置を提供することにある。 The present invention has been made in view of the above problems, and
The purpose is to provide a plasma collection device that can suppress the decline in factor coagulation activity contained in collected plasma and shorten the time it takes to freeze the plasma.
＜問題点を解決するための手段＞
本発明は上記問題点を解決するために、供血者
の静脈から体外に流出された血液が血漿分離器に
よつて血漿を分離され、該分離された血漿が血漿
容器に採取されて、残りの血球濃厚液が供血者の
静脈に返血される採漿装置において、血漿容器に
該容器および該容器に収容された血漿を冷却する
手段を装備したことを特徴とする採漿装置を採用
している。<Means for Solving the Problems> In order to solve the above-mentioned problems, the present invention separates plasma from blood that has flowed out of the body from a blood donor's veins using a plasma separator, In a plasma collection device in which blood cells are collected into a plasma container and the remaining blood cell concentrate is returned to the donor's vein, the plasma container is equipped with a means for cooling the container and the plasma contained therein. It uses a distinctive plasma sampling device.
＜作用＞
本発明の採漿装置を用いた場合、分離・採取さ
れた血漿がただちに10℃〜−10℃に冷却されるの
で、血漿中の第因子凝固活性の減退がほとんど
進行することがない。<Effect> When the plasma collection device of the present invention is used, the separated and collected plasma is immediately cooled to 10°C to -10°C, so the decline of factor coagulation activity in plasma hardly progresses. .
＜実施例＞
次に本発明の実施例について図面に基づいて説
明する。<Example> Next, an example of the present invention will be described based on the drawings.
第１図は本発明の実施例に係わる採漿装置を示
す系統図であり、第２図および第３図は他の実施
例に係わる採漿装置を示す系統図である。 FIG. 1 is a system diagram showing a plasma sampling apparatus according to an embodiment of the present invention, and FIGS. 2 and 3 are system diagrams showing plasma sampling apparatuses according to other embodiments.
第１図は二針法による膜型採漿装置を示すもの
で、１は血漿分離器、２は血漿バツグ、３は
ACD液バツグ、４は採血ライン、５は返血ライ
ン、６は抗凝固剤ライン、７は血漿ライン、８は
血液ポンプ、９は血漿ポンプ、１０は冷却槽であ
る。 Figure 1 shows a membrane-type plasma sampling device using the two-needle method, in which 1 is a plasma separator, 2 is a plasma bag, and 3 is a plasma sampling device.
ACD liquid bag, 4 is a blood collection line, 5 is a blood return line, 6 is an anticoagulant line, 7 is a plasma line, 8 is a blood pump, 9 is a plasma pump, and 10 is a cooling tank.
供血者Ｓの静脈から供給された血液は、採血ラ
イン４に介装された血液ポンプ８によつて採血ラ
イン４を通つて血漿分離器１にポンプ輸送される
が、途中で、同じ血液ポンプ８によつてACD液
バツグ３から抗凝固剤ライン６を通してACD液
が添加される。そしてポンプ輸送された血液は血
漿分離器１によつて血漿を分離され、この分離さ
れた血漿は、血漿ライン７に介装された血漿ポン
プ９によつて血漿ライン７を通つて冷却槽１０に
収納された血漿バツグ２に収容されて10℃〜−10
℃、好ましくは０℃〜−10℃に冷却される一方、
残りの血球濃厚液は返血ライン５を通して供血者
Ｓの別の静脈に戻される。 Blood supplied from the vein of the blood donor S is pumped through the blood collection line 4 to the plasma separator 1 by a blood pump 8 installed in the blood collection line 4. ACD fluid is added from the ACD fluid bag 3 through the anticoagulant line 6 by the ACD fluid bag 3. The pumped blood is then separated into plasma by a plasma separator 1, and the separated plasma is passed through the plasma line 7 into a cooling tank 10 by a plasma pump 9 connected to the plasma line 7. Plasma stored in bag 2 at 10°C to -10°C
°C, preferably between 0 °C and −10 °C, while
The remaining blood cell concentrate is returned to another vein of the donor S through the blood return line 5.
ここで血液ポンプ８は、第１図に示すような二
連式のものが経済的なので好ましいが、抗凝固剤
ライン６と採血ライン４に別々に一連式の血液ポ
ンプを介装しても良い。また血漿分離器１として
は、第１図に示すような膜型血漿分離器の他に遠
心分離器も適用可能である（第３図）。抗凝固剤
としては、保存血用の抗凝固液が用いられ、
ACD液の他にCPD液も使用可能である。 Here, it is preferable that the blood pump 8 be of a dual type, as shown in FIG. . Further, as the plasma separator 1, a centrifugal separator can be used in addition to the membrane type plasma separator shown in FIG. 1 (FIG. 3). As an anticoagulant, an anticoagulant solution for stored blood is used.
In addition to ACD solution, CPD solution can also be used.
血漿容器の材料としては、エチレン−酢酸ビニ
ルコポリマー、ポリエチレン、ポリプロピレン、
ポリ塩化ビニル、ポリウレタン、シリコーン樹
脂、弗素樹脂のような合成高分子材料や、アルミ
ニウム、ステンレス鋼のような金属材料、ガラス
などが挙げられ、とくに容器の形状をバツグ形式
にした場合には、たとえばエチレン−酢酸ビニル
コポリマー製シートで形成された血漿バツグが低
温での耐性がすぐれており好適である。 Materials for plasma containers include ethylene-vinyl acetate copolymer, polyethylene, polypropylene,
Synthetic polymer materials such as polyvinyl chloride, polyurethane, silicone resin, and fluororesin, metal materials such as aluminum and stainless steel, and glass are included.Especially when the container is shaped like a bag, for example, Plasma bags made of ethylene-vinyl acetate copolymer sheets are preferred because they have excellent resistance at low temperatures.
冷却手段としては、水冷式、空冷式、電気式、
電子式などの冷却手段のほか、氷水、氷入り食塩
水、アルコール混合水、グリコール類混合水、ア
ルコール類、ドライアイスなどを媒体とする冷却
手段が挙げられるが、第１図には簡便法として、
氷水や氷水入り食塩水、ドライアイス入りエチレ
ングリコール水媒体などを収容した冷却槽を用い
た方法が示されている。 Cooling methods include water cooling, air cooling, electric,
In addition to electronic cooling methods, there are cooling methods using ice water, salt water with ice, water mixed with alcohol, water mixed with glycols, alcohol, dry ice, etc., but Fig. 1 shows a simple method. ,
A method using a cooling tank containing ice water, saline solution containing ice water, ethylene glycol aqueous medium containing dry ice, etc. is shown.
次に第２図についてであるが、第２図は単針法
による膜型採漿装置を示すもので、第１図の二針
法による採漿装置とは、
採血者Ｓの血液に留置される留置針が１本で
あり、１本の留置針で採血と返血とが行われ
る。 Next, regarding Figure 2, Figure 2 shows a membrane-type plasma sampling device using a single needle method, and the plasma sampling device using a two-needle method shown in Figure 1 is a device that is placed in the blood of person S. There is only one indwelling needle, and one indwelling needle is used to collect blood and return blood.
採血と返血が同じ採・返血ライン４を通して
行われる。 Blood collection and blood return are performed through the same blood collection/return line 4.
採・返血ライン４に介装された血液ポンプ８
の回転が採血時と返血時で逆転される。 Blood pump 8 interposed in blood collection/return line 4
The rotation of the blood is reversed between blood collection and blood return.
血液ポンプ８がACD液ポンプを兼ねること
ができず、従つて抗凝固剤ライン６に別途
ACD液ポンプ１３が介装されている。 The blood pump 8 cannot also serve as the ACD fluid pump, so a separate line is added to the anticoagulant line 6.
An ACD liquid pump 13 is interposed.
血液ポンプ８の下流側に、血液循環ポンプ１
４と血漿分離器１と血液貯留容器１１とがこの
順序で接続連通された血液循環ライン１２が構
成されており、採・返血ライン４が該血液循環
ライン１２と、血液貯留容器１１と血液循環ポ
ンプ１４の間で接続連通している。 A blood circulation pump 1 is provided downstream of the blood pump 8.
4, plasma separator 1, and blood storage container 11 are connected and communicated in this order to form a blood circulation line 12. The circulation pumps 14 are connected and communicated with each other.
という点で異つている。They are different in this respect.
採血者Ｓからの血液は、血液ポンプ８によつて
採・返血ライン４を通り、血液循環ポンプ１４に
より血液循環ライン１２を通つて血漿分離器１に
ポンプ輸送されるが、血液ポンプ８の上流側で
ACD液ポンプ１３によつてACD液バツグ３から
抗凝固液ライン６を通してACD液が添加される。
そしてポンプ輸送された血液は血漿分離器１によ
つて血漿を分離され、この分離された血漿は第１
図の場合と同様に処理される一方、残りの血球濃
厚液は、血液循環ポンプ１４によつて、血液循環
ライン１２を血液貯留容器１１→血液循環ポンプ
１４→血漿分離器１の順に循環される。採血を続
けていくと、血液循環ライン１２内に、供給され
た血液と採取された血漿の差に相当する血球濃厚
液が蓄積されることになるので、血液貯留容器１
１内の液位は徐々に上昇し、やがて該容器１１内
が満タンになる。そこで血液貯留容器１１内が満
タンになる前に血球濃厚液を供血者に戻す必要が
あるが、この場合には血液循環ポンプ１４の運転
をそのままにして、血液ポンプ８の回転を逆転さ
せればよい。従つてこの採漿装置では連続的な血
漿採取が可能である。 Blood from the blood collector S is pumped through the blood collection/return line 4 by the blood pump 8 and then pumped to the plasma separator 1 through the blood circulation line 12 by the blood circulation pump 14. on the upstream side
ACD fluid is added from ACD fluid bag 3 through anticoagulant fluid line 6 by ACD fluid pump 13 .
Then, the pumped blood is separated into plasma by a plasma separator 1, and this separated plasma is
The remaining blood cell concentrate is processed in the same manner as shown in the figure, while the remaining blood cell concentrate is circulated through the blood circulation line 12 in the order of blood storage container 11 → blood circulation pump 14 → plasma separator 1 by blood circulation pump 14. . As blood collection continues, blood cell concentrate corresponding to the difference between the supplied blood and the collected plasma will accumulate in the blood circulation line 12.
The liquid level in container 1 gradually rises, and eventually the container 11 becomes full. Therefore, it is necessary to return the blood cell concentrate to the donor before the blood storage container 11 is full, but in this case, the rotation of the blood pump 8 should be reversed while the blood circulation pump 14 remains in operation. Bye. Therefore, continuous plasma collection is possible with this plasma collection device.
尚、第２図の採漿装置において、採・返血ライ
ン４と血液循環ライン１２との接続点に三方コツ
クなどの流路切替手段を設けても良く、この場合
には血液ポンプ８を省略可能であるが、断続的な
血漿採取となる。 In the plasma collection device shown in FIG. 2, a flow path switching means such as a three-way socket may be provided at the connection point between the blood collection/return line 4 and the blood circulation line 12, and in this case, the blood pump 8 may be omitted. It is possible, but it will require intermittent plasma collection.
次に第３図についてであるが、第３図は二針法
による遠心分離型採漿装置を示すもので、第１図
において血漿分離器として遠心分離器１５を採用
したものである。血液ポンプは採血用の採血ポン
プ１６と返血用の返血ポンプ１７の２つが必要で
あり、ACD液ポンプ１３は採血ポンプ１６を二
連式にすることにより省略可能である。 Next, referring to FIG. 3, FIG. 3 shows a centrifugal plasma sampling device using a two-needle method, in which the centrifugal separator 15 in FIG. 1 is used as the plasma separator. Two blood pumps, a blood collection pump 16 for blood collection and a blood return pump 17 for blood return, are required, and the ACD liquid pump 13 can be omitted by making the blood collection pump 16 a dual type.
このタイプの採漿装置の作用については第１図
に示す採漿装置とほぼ同じである。 The operation of this type of plasma sampling device is almost the same as that of the plasma sampling device shown in FIG.
＜発明の効果＞
以上説明してきたことから明らかなように、本
発明に係る採漿装置を採用することにより、血漿
中の第因子凝固活性の減退を防ぐことができ
る。<Effects of the Invention> As is clear from the above explanation, by employing the plasma collection device according to the present invention, reduction in factor coagulation activity in plasma can be prevented.
第１図は本発明の実施例に係わる採漿装置を示
す系統図であり、第２図および第３図は他の実施
例に係わる採漿装置を示す系統図である。
＜主な符号の説明＞、１：血漿分離器、２：血
漿バツグ、４：採・返血ライン、５：返血ライ
ン、７：血漿ライン、８：血液ポンプ、９：血漿
ポンプ、１０：冷却槽、１２：血液循環ライン、
１４：血液循環ポンプ、１５：遠心分離器。
FIG. 1 is a system diagram showing a plasma sampling apparatus according to an embodiment of the present invention, and FIGS. 2 and 3 are system diagrams showing plasma sampling apparatuses according to other embodiments. <Explanation of main symbols> 1: Plasma separator, 2: Plasma bag, 4: Blood collection/return line, 5: Blood return line, 7: Plasma line, 8: Blood pump, 9: Plasma pump, 10: Cooling tank, 12: Blood circulation line,
14: Blood circulation pump, 15: Centrifugal separator.
Claims (1)
漿分離器によつて血漿を分離され、該分離された
血漿が血漿容器に採取されて、残りの血球濃厚液
が供血者の静脈に返血される採漿装置において、
血漿容器に該容器および該容器に収容された血漿
を冷却する手段を装備したことを特徴とする採漿
装置。 ２ 冷却温度が10℃〜−10℃である特許請求の範
囲第１項記載の採漿装置。 ３ 冷却温度が０℃〜−10℃である特許請求の範
囲第２項記載の採漿装置。[Scope of Claims] 1. Plasma is separated from the blood that flows out of the body from the donor's veins by a plasma separator, the separated plasma is collected into a plasma container, and the remaining blood cell concentrate is used for the donor blood. In a blood sampling device that returns blood to a person's vein,
A plasma collection device characterized in that a plasma container is equipped with a means for cooling the container and the plasma contained in the container. 2. The serum sampling device according to claim 1, wherein the cooling temperature is 10°C to -10°C. 3. The serum sampling device according to claim 2, wherein the cooling temperature is 0°C to -10°C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61257931A JPS63111877A (en) | 1986-10-29 | 1986-10-29 | Plasma sampling apparatus and method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61257931A JPS63111877A (en) | 1986-10-29 | 1986-10-29 | Plasma sampling apparatus and method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63111877A JPS63111877A (en) | 1988-05-17 |
| JPH0574377B2 true JPH0574377B2 (en) | 1993-10-18 |
Family
ID=17313184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61257931A Granted JPS63111877A (en) | 1986-10-29 | 1986-10-29 | Plasma sampling apparatus and method |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63111877A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014168701A (en) * | 2008-08-12 | 2014-09-18 | Termo Bct Inc | System and method for collecting plasma protein fraction from separated blood components |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006067810A1 (en) * | 2004-12-20 | 2006-06-29 | Angelantoni Industrie Spa | Energy-saving climatic test chamber and method of operation |
-
1986
- 1986-10-29 JP JP61257931A patent/JPS63111877A/en active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014168701A (en) * | 2008-08-12 | 2014-09-18 | Termo Bct Inc | System and method for collecting plasma protein fraction from separated blood components |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS63111877A (en) | 1988-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH01502400A (en) | Blood cell washing system and method | |
| US4025618A (en) | Method for separation of cryoprecipitate from blook plasma | |
| JP4528863B2 (en) | Apheresis equipment | |
| EP0016014A4 (en) | Process for separating blood cell-containing liquid suspensions by filtration. | |
| JPH114682A (en) | Preservation of nucleated cells, composition for the same and segregation of yukakusaihou | |
| US5217618A (en) | Plasma purification treatment | |
| JPH0574377B2 (en) | ||
| Weniger et al. | Reduction of bank blood requirements in cardiac surgery | |
| IL47945A (en) | Method and apparatus for the separation of cryprecipitate separation of cryoprecipitate from blood plasma | |
| US5286388A (en) | Method for neutralizing heparin in whole blood taken from an extracorporeal circuit | |
| JP3283641B2 (en) | Blood processing method | |
| JP3005019B2 (en) | Kit and method for preparing cryopreserved blood | |
| JPH10179731A (en) | Blood treating device and blood treatment | |
| Högman et al. | A simple method for the preparation of microaggregate‐poor whole blood | |
| US20230043534A1 (en) | Systems and Methods for Converting an Apheresis Fluid Processing Circuit to Single or Double Needle Mode | |
| Schill | The optimal preservation of the patient's hematocrit when cardiopulmonary bypass is required | |
| JP4217843B2 (en) | Method for producing fibrin glue preparation | |
| EP3669904A1 (en) | Methods and systems for platelet cryopreservation | |
| JPS60256466A (en) | Serum sampling apparatus | |
| JPS63115569A (en) | Plasma sampling apparatus | |
| JPH06269497A (en) | Method for preparing component separated blood for refrigeration | |
| JPS6036059A (en) | Serum sampling apparatus | |
| Kurtz et al. | A New Approach to Washing Red Blood Cells Frozen with a High Concentration of Glycerol in a Special Freezing Container 1 | |
| JPH0779838B2 (en) | Treatment device for progressive cerebral thrombosis | |
| JPH0793945B2 (en) | Donorpheresis device |